licensingGSK ends Alector neuroscience deal after trial failuresGSK has pulled out of its neuroscience collaboration with Alector, ending a 2021 alliance that began with a $700m upfront payment but has since been hit by two clinical setbacks. more ➔
fundraisingAlchemab extends Series A with £25m from British Business BankCambridge-based Alchemab Therapeutics has added £25m (€29m) to its Series A financing, taking the round to £109m (€128m) and giving the UK biotech fresh capital to advance its AI-enabled antibody … more ➔
licensingAZ buys ex-China rights to Sino’s COPD drug for $2.1bnAstraZeneca has moved to strengthen its respiratory pipeline with a late-stage Chinese COPD asset, striking a deal that gives it a lower-cost shot at a market MSD recently entered through its $10bn Verona … more ➔
licensingBoehringer licenses PVT virus platform for cancer vaccinesBoehringer Ingelheim has licensed oncology rights to Prime Vector Technologies’ (PVT) Orf virus platform to develop a new generation of cancer vaccines. more ➔
Start-upGraph Therapeutics raises $5m to advance I&I pipelineAustria’s Graph Therapeutics has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on … more ➔
fundraisingEG 427 rebrands as Cyllene and cashes in €33m Series CFrench gene therapy biotech EG 427 has rebranded as Cyllene Therapeutics and raised €33m in a Series C round to push its lead neuro-urology candidate EG110A toward late-stage clinical testing. more ➔
Scripta TherapeuticsOpinionWhere will AI actually move the needle in drug discovery?Biotech’s biggest opportunity is not simply to generate more compounds faster, but to improve the biological hypotheses behind them and help focused companies turn shared datasets, better models and … more ➔
M&ANovartis buys UK ADC biotech Myricx Bio in up to $1.5bn dealNovartis has agreed to acquire UK-based Myricx Bio for up to $1.5bn, adding a preclinical antibody-drug conjugate platform built around a novel payload class for solid tumours. more ➔
licensingGenentech signs $490m breast cancer deal with AstexRoche’s Genentech has signed an oncology research deal with Astex, hoping the UK-based biotech will hit the jackpot again after a similar tie-up with rival Novartis produced the blockbuster breast … more ➔
licensingAstraZeneca returns to CSPC with $1.77bn kidney dealAstraZeneca has signed another deal with China’s CSPC Pharmaceutical Group, this time to discover and develop siRNA drug candidates for kidney diseases. more ➔
Scripta Therapeutics
